The Agency for Healthcare Research and Quality (AHRQ) has released a draft paper examining the impact of changes in payment policies on clinical trials. The report discusses the relationship between third-party payments and the recruitment and retention of participants in clinical trials. Among the conclusions of the report: payment policies do affect evidence development in that their impact on clinical trial enrollment results in slower accrual, longer time to complete studies, and the occasional early termination of a study due to a lack of participation. Further, the reports suggest that better coordination among government agencies and between government, third-party payors, sponsors, and trial sites is necessary. Comments on the report are due Jan. 23.
Information: Go to http://www.ahrq.gov/clinic/ta/paypolicy/paypolicy.pdf
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.